Form D · Pharmaceuticals

AllergEase Inc

Danville, VA · CIK 0001569902

Offering snapshot reported Apr 3, 2014 · SEC filing

Reported sold
$1.08M
Offering amount: $1.5M
Investors reported
42
Form D · investor count
Minimum accepted
$12.5K
Reported outside-investor minimum
First sale
Feb 4, 2013
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$540K$1.08MFeb 19, 2013: $407,500.00Feb 19, 2013Apr 3, 2014: $1,080,959.00Apr 3, 2014

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$407,500 → $1,080,959
  • Reported investors7 → 42

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Apr 3, 2014Amendment$1,080,959$673,459vs Feb 19, 201342SEC filing
Feb 19, 2013Initial$407,500No comparison7SEC filing

Offering details

Securities
Debt, Option to acquire, Security to be acquired
Exemptions
06c
Duration over one year
Yes
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-192012

Source: Form D, filed Apr 3, 2014. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Dan Engel Director
Luke Nelson Fry Director
Omar Javery Director, Executive
Zeeshan Kaba Director, Executive
Xandra Laskowski Director
William Pascarella Director
Nancy Lai Sum Wong Director, Executive
Sam Yousefzadeh Director

Issuer details

Industry: Pharmaceuticals (See others in industry)

Address:
541 Bridge Street Suite 2
Danville, VA, 24541-1405